Advantx is a person-centered biopharmaceutical company focused on developing disease-modifying therapeutics for neurological disorders through a deep understanding of protein mechanisms.
Headquartered in New York and founded in 2022 by the Advantx Foundation, Advantx Pharmaceuticals Inc. is a biopharmaceutical company that combines a deep understanding of cell biology with unique insights into diseases of the central nervous system to develop a comprehensive portfolio of innovative therapies under the direction of a team experienced in drug discovery, clinical development and bringing new drugs to market.
Meet our team
Advantx Pharmaceuticals is revolutionizing the development of innovative therapies that not only modulate specific functions of disease-causing proteins and their pathways, as conventional drugs approach but also restore protein homeostasis. By incorporating proteostasis, we restore the folding of new proteins and the degradation of old or misfolded proteins, while also restoring cellular function, neuronal growth and vital system balance, and contribute to longevity, placing us at the forefront in the development of disease-modifying therapies for people of all ages suffering from major chronic heterogeneous disorders or rare diseases.
More about our science
“We develop new medicines based on the Sigma science with the confidence that, when they reach the market, will make a significant difference to the lives of patients and their families.”
Joseph Pergolizzi – CEO and President of Advantx Pharmaceuticals
PERSONS FIRST
We keep patients, families, and caregivers front and center in our daily work and collaborate to solve critical scientific and business challenges.
TEAM INTEGRITY
We take responsibility for our actions and are ethically uncompromising and truthful with our customers, partners, and ourselves as a prerequisite for long-term success.
INNOVATION FOCUS
We create value through lasting innovation and maximize our ability to innovate solutions that improve patient care and accelerate the development of cures and therapies.
GLOBAL INCLUSION
We are a multicultural global company and embrace and leverage differences to foster an inclusive community, both internally and externally.
Advantx is the world leader in the science of innovative and pluripotent Sigma receptors.
1996.
SIGMAR1 FIRST CLONED
The concept of “Sigma receptors” arose 40 years ago in a pharmacological study postulating the existence of this type of receptors but was in 1996 when the Sigma-1 receptor was cloned for the first time
2017.
SIGMR2 IDENTIFIED
The Sigma2 receptor was identified in 2017 as an integral membrane protein termed transmembrane protein 97 (TMEM97) and validation of Sigma2 as a drug target begins
2021.
ADVANTX PATENTS
Advantx’s SigmaR1 and SigmR2 selective compound patents expire in 2041, constituting the most complete and advanced generation of therapeutic candidates Sigma
RELATED SCIENTIFIC PUBLICATIONS
Advantx Candidate
ADV462 EAD
Early Alzheimer’s Disease
Selective Sigma-2
Potent Antagonist
Positive Results.